Compare Cincinnati Financial Corporation (CINF) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs 10X Genomics Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.68B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: Cincinnati Financial Corporation is far larger — about 3.5× 10X Genomics Inc's market cap, and Cincinnati Financial Corporation pays a 2.16% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| CINF | TXG | |
|---|---|---|
Market Cap | $26.68B | $7.64B |
Sector | Financials | Health |
52-Week High | $192.03 | $58.57 |
52-Week Low | $149.79 | $11.34 |
Enterprise Value | $25.80B | $7.17B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $176.86, down 1.22% on the day, with a bearish technical signal but strong fundamentals including a P/E of 8.35 and ROE of 21.48%. Recent Q2 2026 earnings missed estimates at $1.43 per share versus $1.84 expected, though revenue grew year-over-year. The company maintains robust cash flow, with 2025 operating cash flow at $3.11 billion, and a consistent dividend history, including a recent $0.94 payout.
Outlook is mixed: valuation appears attractive with analyst consensus price target of $195, but near-term headwinds include catastrophe losses and commercial lines weakness. Long-term growth is supported by premium expansion and investment income, though investors face risks from underwriting volatility and economic sensitivity.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
